Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers by Butler, Stephen F et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
Harm Reduction Journal
Open Access Research
Development and validation of an Opioid Attractiveness Scale: a 
novel measure of the attractiveness of opioid products to potential 
abusers
Stephen F Butler*1, Christine Benoit1, Simon H Budman1,2, 
Kathrine C Fernandez1, Cynthia McCormick3, Synne Wing Venuti1 and 
Nathaniel Katz1,4
Address: 1Pain and Opioid Division, Inflexxion, Inc., 320 Needham St., Ste. 100, Newton, MA 02464, USA, 2Department of Psychiatry, Harvard 
Medical School, 25 Shattuck St, Boston, MA 02115, USA, 3McCormick Consultation, LLC, 9127 Friars Rd., Bethesda, MD 20817, USA and 
4Department of Anesthesiology, Tufts University School of Medicine, 136 Harrison Ave, Boston, MA 02111, USA
Email: Stephen F Butler* - sfbutler@inflexxion.com; Christine Benoit - cbenoit@inflexxion.com; 
Simon H Budman - simonbudman@inflexxion.com; Kathrine C Fernandez - kfernandez@inflexxion.com; 
Cynthia McCormick - cgmc@comcast.net; Synne Wing Venuti - svenuti@inflexxion.com; Nathaniel Katz - natpaulkatz@aol.com
* Corresponding author    
Abstract
Background: The growing trends in opioid abuse, assessment of the abuse liability of prescription opioid
products, and growing efforts by the pharmaceutical industry to develop 'abuse-resistant' formulations highlight a
need to understand the features that make one product more 'attractive' than another to potential abusers. We
developed a scale to measure the 'attractiveness' of prescription opioids to potential abusers, and used the scale
to measure the relative attractiveness of 14 opioid analgesic products.
Methods: First, the concept of attractiveness was empirically defined with a group of prescription opioid abusers
and experts in opioid abuse using a process called Concept Mapping. Abuse liability consisted of two components:
factors intrinsic to the drug formulation (e.g., speed of onset, duration) and factors extrinsic to drug formulation
(e.g., availability, availability of alternatives, cost). A 17-item Opioid Attractiveness Scale (OAS) was constructed,
focusing on factors intrinsic to the drug product.
Results: A total of 144 individuals participated in tests of validity and reliability. Internal consistency was excellent
(Cronbach's α = 0.85–0.94). Drug rankings based on OAS scores achieved good inter-rater agreement (Kendall's
W 0.37, p < 0.001). Agreement on drug OAS scores between the developmental sample and a confirmation
sample was good (IntraClass Correlations [ICC] of 0.65–0.69). Global ratings of overall attractiveness of the 14
selected opioid products by substance abuse counselors corresponded with the rankings based on OAS ratings
of the abuser group. Finally, substance abuse counselors completed the OAS, yielding a high level of
correspondence with ratings by the abuser group (ICC = 0.83, p = 0.002). The OAS differentiated attractiveness
among 14 selected pharmaceutical opioid products. OxyContin, Dilaudid, and Percocet were ranked highest
(most attractive); Talwin NX and Duragesic were ranked lowest (least attractive).
Conclusion: An initial examination of the psychometric properties of the OAS suggests that it is a valid and
reliable scale. The OAS may be useful in providing important guidance on product features that are attractive to
potential abusers.
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Background
The study of opiate abuse has a long history in the human-
ities and the social sciences, but a limited one in terms of
clinical science and drug development studies [1-5]. Epi-
demiologic data (Substance Abuse and Mental Health
Services Administration [SAMHSA], the National Institute
on Drug Abuse's Monitoring the Future project, and the
Drug Abuse Warning Network [DAWN]) indicate that
non-medical use and abuse of prescription opioids is on
the increase in the United States [6]. Left untreated, opiate
dependence is responsible for significant morbidity and
mortality. For example, use of illicit opiates is associated
with an increased risk of hepatitis C infection, HIV infec-
tion, and other medical consequences such as overdose
[7]. In addition, there has been an increase in uninten-
tional deaths related to opioid medication in several areas
across the United States [8,9].
Misuse and abuse of narcotics has been a subject of med-
ical concern for many years [10-12]. To address this con-
cern, a number of patents have been filed by
pharmaceutical companies for 'abuse resistant' opioid for-
mulations [13]. The pharmaceutical industry continues to
develop drugs with enhanced delivery capabilities [14-
17]. Some of these new formulations have been assumed
to be relatively abuse-resistant, yet their real potential for
abuse is unknown. Given the continuing developments in
new products and formulations reaching the market,
health professionals and those involved in the care and
treatment of substance abusers need a way of assessing the
relative attractiveness of these new products in order to
understand and manage any associated risks to society.
There has been no work done to date examining the qual-
ities that make a specific prescription opioid product
more attractive, or more unattractive, to potential recrea-
tional users/abusers.
To address this need, an Opioid Attractiveness Scale
(OAS) was developed and validated. The OAS is offered as
a sensitive and reliable method for detecting differences in
attractiveness of different prescription opioid products
and formulations to potential abusers.
Methods
The development process consisted of four phases. The
first was to define what makes different prescription opi-
oid products attractive or unattractive to potential abus-
ers, and hence to establish the content of the scale. The
second phase was to generate and evaluate items for the
scale using Concept Mapping. Items generated in this way
underwent a conceptual evaluation process and pilot test-
ing. An alpha version was constructed and examined for
usability in a small pilot. During phase three, a beta ver-
Table 1: Study phases and participants
Study phase Participant category
Phase1: Pre-Concept Mapping Pre-Concept Mapping sample:
• Casual users
• Substance abuse clients
• Pain patients
• Impaired professionals
• Substance abuse experts
Phase 2: Concept Mapping, usability testing Concept Mapping sample:
• Casual users
• Substance abuse clients
• Pain patients
• Impaired professionals
• Substance abuse experts
Usability testing sample:
• Substance abuse clients
• Pain patients
Phase 3: Initial evaluation Developmental sample:
• Casual users
• Substance abuse clients
Phase 4: Assessment of reliability and validation of scale Confirmation sample:
• Casual users
• Substance abuse clients
Validation sample:
• Substance abuse experts
Definitions of participant categories
Casual users: active recreational users of prescription opioids who were not in treatment
Substance abuse clients: persons in treatment for opioid abuse
Pain patients: patients with a history of opioid misuse
Impaired professionals: persons in the medical field who were current or previous prescription opioid abusers
Substance abuse experts: professional substance abuse counselors experienced in treating opioid addictionHarm Reduction Journal 2006, 3:5 http://www.harmreductionjournal.com/content/3/1/5
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sion was then empirically evaluated for reliability and
validity on a developmental sample of substance abuse
clients. In phase four, a final version of the OAS was sub-
jected to cross validation with a new sample of substance
abuse clients and validation against ratings made by pro-
fessionals who treat prescription opioid abuse.
Participants
Participants (stakeholders) included casual users, sub-
stance abuse clients, pain patients, impaired profession-
als, and opioid and substance abuse experts (Table 1).
Experts were recruited through professional referrals. The
remaining stakeholders were recruited via provision of fly-
ers in pain, methadone, and substance abuse clinics
throughout the United States, and via internet advertise-
ments. Interested potential participants called a toll-free
number to obtain additional information about the
study. Using a standardized screener, a research team
member screened all callers. Individuals who consented
and met specific inclusion and exclusion criteria were
involved in the study.
Phase 1: Pre-Concept Mapping
The first step in Concept Mapping involves open-ended
interviews with various stakeholders who were scheduled
for a one-hour interview with research team members.
Interviews were conducted by telephone using a struc-
tured script designed to capture all of the factors that make
different formulations of prescription opioids attractive
and unattractive to individuals with a propensity for sub-
stance abuse. Notes and tape recordings of interviews
were reviewed by the team. The qualitative results of these
interviews were used to inform the focus prompts in the
next stage of Concept Mapping.
Phase 2: Concept Mapping phase and creation of scale
Concept Mapping is an inductive but structured process in
which participants, through brainstorming, generated a
list of specific statements in response to prompts/ques-
tions about the attractiveness of prescription opioid prod-
ucts (developed from the pre-Concept Mapping phase).
Participants were then re-contacted to sort the statements
into conceptual groups and rate each statement using a
A sample opioid information card Figure 1
A sample opioid information card.Harm Reduction Journal 2006, 3:5 http://www.harmreductionjournal.com/content/3/1/5
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Likert-like scale. In this case, statements were rated as to
their importance to attractiveness. Participants completed
this activity by mail or e-mail. Materials were accompa-
nied by detailed instructions and a follow-up phone call
by a research team member. Using multidimensional scal-
ing and cluster analysis, Concept Mapping moves from
the list of statements, in a stepwise fashion, toward more
general concepts. This technique allows the transforma-
tion of qualitative data into a form suitable for rigorous
statistical examination. A pilot scale (alpha version) was
developed as a result of this process.
The alpha version of the OAS was pilot tested with a small
group of stakeholders. The purpose of this exercise was to
test the language of the OAS to make certain respondents
could comprehend the content and understand directions
of the activity. A research team member conducted the
structured pilot interview with each participant. Partici-
pants were asked to use the alpha OAS to judge the attrac-
tiveness of five opioids. Reference cards containing a
picture, the brand name, street names, and other product-
specific information was provided for each opioid as vis-
ual cues. This pilot test resulted in modifications to the
OAS yielding a beta version.
Phase 3: Initial evaluation of the beta OAS
The beta OAS was evaluated empirically with a group of
potential abusers in order to assess the replicability and
reliability of the scale. Ratings were conducted in face-to-
face meetings or remotely (using mailed versions of the
materials accompanied by detailed instructions and a fol-
low-up phone call from a research team member). Partic-
ipants were provided with the OAS rating materials
including an information card for 14 opioid products and
a separate 17-item rating scale for each drug. They then
rated how attractive thespecified feature of the drug prod-
uct was to them using a five-point scale (1 – 'this feature
makes the drug extremely unattractive to try'; 2 – 'this fea-
ture makes the drug somewhat unattractive to try'; 3 – 'this
feature does not affect my interest in trying the drug'; 4 –
'this feature makes the drug somewhat attractive to try'; 5
– 'this feature makes the drug extremely attractive to try').
The word 'try' was featured in the scale instead of the word
'use', in order to determine what would attract new users,
including casual users, to sample new products. Further-
more, this wording allowed for the application of the OAS
to products that, at the time of this study, were not avail-
able in the market, as demonstrated with the fentanyl
matrix patch. Participants used the scale to judge the
attractiveness for abuse of 14 prescription opioid products
(Actiq, Avinza, Dilaudid, Duragesic, Fentanyl matrix
patch, Kadian, MS Contin, OxyContin, Percocet, Stadol
Nasal Spray, Suboxone and Talwin NX) shown to them in
pictorial form on information cards (Figure 1), including
a transdermal formulation of fentanyl in a drug-in-adhe-
sive, matrix patch formulation, not then marketed in the
United States. These 14 products were chosen to accom-
modate the following goals: to include the most com-
monly prescribed opioids in the United States; to include
drug products felt to represent a spectrum of abuse liabil-
ities; to include both immediate- and sustained-release
products; and to include drugs designed and perceived to
be relatively abuse-resistant (e.g. Talwin-NX and Subox-
one). Oxycodone combination products were felt to be
similar enough to hydrocodone combinations with
respect to abuse liability so that only the latter were
included.
The information cards were developed by a team of three
pharmacists and two physicians, who utilized informa-
tion in the public domain to specify the features of each
drug required for each item of the OAS (e.g., onset of
action, duration of effect, etc).
Phase 4: Cross validation and criterion validation of the 
scale
An important aspect of scale development is cross valida-
tion, a necessary step to ensure that the results of the rat-
ings and rankings achieved during scale construction are
replicable and not simply an artifact associated with a par-
ticular sample. Thus, the procedure was repeated with a
new group of potential abusers. The assessment methods
for this group of substance abuse clients were identical to
those used with the developmental sample. In addition, it
was considered important to establish some 'outside' cri-
terion against which to compare the substance abusers'
OAS ratings. Since there is no existing 'gold standard', we
compared results obtained by clients with ratings of the
same drugs made by professional substance abuse coun-
selors experienced in treating opioid addiction.
Statistical methods
Internal consistency of the OAS was assessed using stand-
ard procedures for calculating coefficient α [18]. Agree-
ment on the extent to which the various drugs are
'attractive' was calculated two ways. First, agreement on
the relative ranking of the medications was calculated by
ordering drugs according to their OAS score and using
Kendall's Coefficient of Concordance statistic (Kendall's
W) [19] to determine whether the concordance was signif-
icant. Secondly, comparison of the extent to which differ-
ent groups assigned similar OAS scores to the same drug
were calculated using the IntraClass Correlation (ICC) sta-
tistic, an accepted method for examining the correspond-
ence of the ratings of two or more raters judging the same
items. Confirmation of the OAS was established by calcu-
lating the ICC across all drugs being evaluated in order to
demonstrate that the output of the scale is replicable. As
an additional test of validity, agreement between rankings
by potential abusers and those by substance abuse coun-Harm Reduction Journal 2006, 3:5 http://www.harmreductionjournal.com/content/3/1/5
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selors was assessed using the Kendall's W test. The study
was approved by the Inflexxion Institutional Review
Board.
Results
Participants
A total of 144 individuals (opioid users and profession-
als) participated in the development and testing of the
OAS. Study participants were recruited predominantly
from the United States and included casual prescription
opioid users (active recreational users who were not in
treatment); substance abuse clients (persons in treatment
for opioid abuse); pain patients with a history of opioid
misuse; impaired professionals (persons in the medical
field who were current or previous prescription opioid
abusers); and experts (professional substance abuse coun-
selors experienced in treating opioid addiction; Table 2).
Sixteen key stakeholders were recruited for Phase 1,
including four opioid abuse experts, three impaired pro-
fessionals, three casual prescription opioid users, two per-
sons in treatment for opiate abuse, and four pain patients
with a history of opioid misuse. Thirty-six stakeholders
were recruited and completed Concept Mapping phases,
including six pain patients, seven casual users, 14 sub-
stance abuse clients in treatment, three impaired profes-
sionals, and six substance abuse/opioid experts. Four
individuals participated in the usability testing of the
alpha version of the OAS. Face-to-face usability of the
scale was tested using two substance abuse clients and two
pain patients from various socio-economic and racial/eth-
nic backgrounds.
Pre-Concept Mapping
Eight key areas were consistently reported to be an indica-
tor of attractiveness. The most prevalent theme was the
quality of the high, with participants reporting that the type
of high they were seeking would inform their choice of
prescription opioid. Duration of the high was also an attrac-
tive quality, as was the preference for prescription opioids
in pill form which was considered to be more convenient
than other delivery systems due to ease of swallowing,
chewing, or crushing and snorting. A further factor influ-
encing attractiveness was availability  (via prescription,
street or 'club' supply), the choice of prescription opioid
dependent on what medications would be available at
any point in time.
Cost  was another component of the attractiveness of a
product for abuse for many subjects; although some par-
ticipants claimed that cost was not an issue, this appeared
to be because they received free medications or because
money in general was not an issue for them. Side effects
and withdrawal effects were also considered important fac-
tors, as was peer influence, which seems to inform users
which products are attractive and which should be
avoided. Finally, the real or perceived dangers associated
with a drug were a factor influencing attractiveness, but
Table 2: Study participants and demographics
Number (%) of participants
Characteristic Pre-Concept 
Mapping
Concept 
Mapping
Developmental 
sample
Confirmation 
sample
Substance abuse 
experts (validation) 
sample
Total number of participants 16 36 38 42 12
Age (years) Mean ± SD 39.08 ± 9.38 38.2 ± 9.0 39.3 ± 12.2 37.8 ± 9.7 45.5 ± 8.1
Gender 8 (50) male 10 (33) male 22 (58) male 27 (64) male 6 (50) male
8 (50) female 20 (67) female 15 (39) female 13 (31) female 6 (50) female
1 (3) missing 2 (5) missing
Race
- White 15 (94) 22 (73) 23 (61) 23 (55) 9 (75)
- African-American 1 (6) 2 (7) 3 (8) 6 (14) 0
- Hispanic 0 5 (17) 10 (26) 11 (26) 3 (25)
- Other 0 1 (3) 2 (5) 1 (2) 0
- Missing 0 0 0 1 (2) 0
Residence
- Urban 12 (81) 25 (83) 28 (74) 33 (79) 5 (42)
- Rural 3 (19) 5 (17) 10 (26) 8 (19) 7 (58)
-  M i s s i n g 0000 0
Casual users 3 (19) 7 (19) 8 (21) 9 (21) 0
Substance abuse clients 2 (12) 14 (39) 30 (79) 33 (79) 0
Pain patients 4 (25) 6 (17) 0 0 0
Impaired professionals 3 (19) 3 (8) 0 0 0
Substance abuse experts 4 (25) 6 (17) 0 0 0Harm Reduction Journal 2006, 3:5 http://www.harmreductionjournal.com/content/3/1/5
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were not considered a deterrent by some of the long-term
prescription opioid abuser participants.
Concept Mapping and development of the scale
In the brainstorming phase, the participants generated
over 2000 separate statements regarding factors that make
opioids attractive or unattractive. These statements were
reviewed to remove duplicates and nonsensical entries
and to combine similar statements. As a result of this
process, 109 statements were retained for use in the sort-
ing and rating phase (see example statements in Table 3).
The sorting and rating process resulted in the definition of
three dimensions of the scale: positive features of the
preparation, negative features of the preparation and
social milieu effects of the preparation. To clarify, in this
project, social milieu was operationally defined to include
such phenomena as the product's availability, cost, and
possible stigmas that vary among geographic locations
and social networks.
Based on average ratings of importance for the statements
within each dimension, the most important of the three
dimensions (mean rating for dimension = 3.83) was the
positive features of the preparation (e.g., statements such
as 'can be safely injected', 'easily dissolved', 'long-lasting
high' and 'multiple uses can be obtained from one unit').
A mean rating of 3.57 was obtained for social milieu
effects of the preparation (e.g., statements such as 'easily
concealed or hidden', 'easy to get from pharmacy, doctor,
street', 'a lot of information is available on the internet',
and 'less likely to lead to arrest or bust'). The dimension
characterizing negative features of the formulation was
rated the lowest with a mean rating of 2.94.
Alpha version creation and pilot usability testing
Based on the Concept Mapping results, an alpha version
of the OAS was created with 22 items reflecting the three
dimensions of positive and negative features of the prod-
uct preparation, as well as the social milieu dimension.
The usability testing resulted in some modifications
including: providing layman's definitions of certain
words, clarifying the DEA classifications of drugs; reduc-
ing the reading grade-level to 7.5 (Flesch Kincaid Grade
Level); and, removing 'social milieu' items due to lack of
agreement among the raters and the potential influence of
changing context. While social milieu-type questions may
carry important variance with respect to how individual
raters view the attractiveness of various medication prepa-
rations, such items may also reflect situational variables
not directly tied to qualities of the product itself. Thus,
whether a product is easy or difficult to obtain at a phar-
macy may be an important consideration on the street,
but it is not necessarily related to the product itself, and
may change from time to time or place to place. Addition-
ally, social milieu items are very subjective, and can vary
between stakeholder populations and within stakeholder
groups. Finally it was determined, based on participant
feedback, that participants should be presented with pic-
tures of the opioid to assist them in the rating activity by
providing a visual cue (see Figure 1). Brand and street
names were also included on the opioid information card
based on the results of usability testing. The modified beta
version of the OAS was thus reduced to 17 items (see
Table 4).
Stakeholders used the beta version of the OAS to rate 14
opioid products. Although all participants reported using
at least one of the 13 actual drugs (see Table 5, excluding
Table 3: Examples of statements generated by the Concept Mapping process
This form of opioid medication makes you nauseous
This form of opioid medication results in a high that allows you to function (go to work, drive etc)
This form of opioid medication doesn't affect your appearance
This form of opioid medication can be safely injected
This form of opioid medication is preferred by my friends
This form of opioid medication makes you indifferent
This form of opioid medication has a greater addiction potential
This form of opioid medication gives you a whole-body buzz/rush
This form of opioid medication is painful to use
This form of opioid medication makes me feel like I can do anything
This form of opioid medication makes me feel I can do more than usual
This form of opioid medication makes you excited and hyper
This form of opioid medication makes you feel sleepy
This form of opioid medication makes you incoherent (cannot communicate with others)
This form of opioid medication can be easily concealed or hidden
This form of opioid medication creates pleasant hallucinations
This form of opioid medication creates tolerance easily (must take more to get high)
This form of opioid medication heightens sexual feelings
This form of opioid medication makes you thirsty ('cotton mouth')
This form of opioid medication relieves your anxietyHarm Reduction Journal 2006, 3:5 http://www.harmreductionjournal.com/content/3/1/5
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the hypothetical transdermal matrix patch formulation of
fentanyl), raters did not need to have experience with
every drug. Rather, ratings were based on information
provided to the participants on the information cards.
Raters took an average of 5 minutes to complete each
scale.
Scoring of the scale (development sample)
A number of different methods of obtaining an overall
OAS score were considered, including the sum of the
items scored, the mean score, Z-score transformation, cal-
culation based on attractive items only and a weighted
composite. In order to select from these options, two cri-
teria were used: agreement among the raters and the
extent to which the scoring methods differentiated the
drugs. In general, the various composite scores yielded
similar information (intercorrelations of the different
scores were all >0.80, and all but one were ≥0.88). The
sum and mean composite scores, however, best met the
criteria.
Calculation of mean composite scores from 38 raters
showed that means ranged from a high of 3.73 for Vicodin
(most attractive) to a low of 2.58 for Duragesic (least
attractive). Table 5 shows the mean ranks of the various
medications for all 38 raters. To arrive at these ranks, a
ranking of all 14 drugs from least to most attractive (1 to
14) was developed for each individual rater based on his
or her composite scores for the drug. The mean rank was
then calculated and ordered. Again, this process resulted
in Vicodin receiving the highest rank (11.94) and Durag-
esic the lowest (2.98). Rankings based on the sum scores
of the various medications are similar.
Cross validation and criterion validation of the scale 
(confirmation sample)
Reliability (internal consistency) was calculated on data
collected from a new, confirmation sample of 42 sub-
stance abusers (see Table 2). The appropriate level of
internal consistency is determined by convention, and a
coefficient α of ≥0.70 is generally considered good [18]. In
this study, internal consistency of the OAS was calculated
for each drug and was found to be excellent (α = 0.85–
0.94).
Cross-validation of the reliability of the scale as well as the
ratings and rankings produced by the OAS is an important
part of the validation process. Ratings of the confirmation
sample resulted in the rankings shown in Table 6. It is evi-
dent that the order of the drugs was different from the ini-
Table 4: Content of OAS items: each is rated on a five-point 
scale
1 Painful to snort or inject
2 Ability to conceal or hide
3 Duration of withdrawal symptoms
4 Messy to use
5 Ability to change into another form for recreational use
6 Presence of toxic metabolites
7 Solubility in water, vinegar, alcohol, etc
8 This medication's duration of effect
9 Short onset (works quickly)
10 Potency compared to morphine
11 Contains waxes, gums, binders, fillers or other impurities
12 Contains an opioid antagonist
13 Divisible into smaller doses
14 Ability to use in different ways (snort, smoke, eat, IV, etc) to get 
different highs
15 Designed in a way that is difficult to abuse to get a high
16 This medication comes in high doses
17 Drug considered to have high (or low) potential for abuse (DEA 
classification)
Note: The specific item for each drug is worded so that a higher rating 
reflects a greater degree of 'attractiveness.'
Table 5: Mean ranks of drugs: OAS ratings in descending order for development sample using two scoring approaches
Product order for mean 
composite
Mean rank for mean 
composite
Product order for sum 
composite
Mean rank for sum composite
Vicodin 11.94 Vicodin 11.94
OxyContin 10.39 OxyContin 10.39
Talwin NX 10.29 Talwin NX 10.27
MS Contin 9.39 MS Contin 9.41
Methadone 9.08 Methadone 8.89
Dilaudid 7.42 Dilaudid 7.45
Actiq 7.12 Actiq 7.14
Avinza 6.83 Avinza 6.86
Kadian 6.73 Kadian 6.74
Percocet 6.47 Percocet 6.52
Suboxone 6.32 Suboxone 6.32
Fentanyl matrix patch 5.52 Fentanyl matrix patch 5.50
Stadol Nasal Spray 4.52 Stadol Nasal Spray 4.58
Duragesic fentanyl reservoir patch 2.98 Duragesic fentanyl reservoir patch 2.98Harm Reduction Journal 2006, 3:5 http://www.harmreductionjournal.com/content/3/1/5
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tial rankings described above. OxyContin had the highest
attractiveness score for both mean and sum composite
values, but Duragesic remained the least attractive of the
products rated.
Despite changes in the ranks of individual drugs between
the developmental and confirmation samples, the level of
agreement on the actual scores assigned to the individual
drugs was examined using the ICC statistic. Traditionally,
interpretations of the magnitude of ICCs assume that val-
ues >0.80 represent 'perfect' agreement; 0.61–0.80 is sub-
stantial; 0.41–0.60 is moderate; and 0.21–0.40 is fair
reliability [20]. For the mean composite score the ICC was
0.65 (p = 0.037); for the sum composite score, the value
was 0.69 (p = 0.022). These results are both significant
and reflect substantial agreement, suggesting that the
results of the OAS were replicated in the cross validation.
In order to relate OAS scores assigned by a group of poten-
tial abusers to some outside criterion, rankings made by
substance abusers were compared with rankings of the
drugs made by substance abuse counselors. Reasonably
good correspondence was found between the two groups.
Kendall's W was 0.89 (p = 0.039) for the mean composite
scores and 0.87 (p = 0.048) for the sum composite scores.
This suggests that the relative rankings of the drugs by the
two groups were comparable. Similarly, direct compari-
sons of counselors' and substance abusers' ratings showed
very high agreement (ICC = 0.83, p = 0.002). Considering
that these raters were not trained to agree, this level of
agreement is very high. Taken together, these data suggest
that the OAS provides a reasonably robust measure of the
relative attractiveness for abuse of specific opioid analge-
sics.
Further examination of the drug ratings
In order to examine the clinical meaningfulness of differ-
ences in attractiveness ratings, the average effect size
(Cohen's D) of each drug, as rated by substance abusers,
was compared to every other drug rated.Drugs with small
average effect sizes (approximately 0.20) are more similar
to other drugs in their ratings, while those with large aver-
age effect sizes (approximately 0.80) are more likely to be
different from most other drugs. Figure 2 shows a striking
difference at the extremes, particularly between OxyCon-
tin and Duragesic. Clearly, OxyContin was viewed as
much more attractive than the other drugs, while Durage-
sic is much less attractive to this group of abusers than all
of the other medications investigated.
Comparison of the ratings of potential substance abusers
with those of the counselors reinforced the extreme posi-
tions of OxyContin and Duragesic as the most and least
attractive for abuse, respectively (Figure 3).
Discussion
The OAS was developed empirically from patient and pro-
fessional input. The scale development process included
content validity, initial empirical testing, cross validation,
and comparison with an outside criterion. Results indi-
cate that the OAS appears to be a reliable and valid meas-
ure of the attractiveness for abuse of opioid analgesic
products, yielding stable ratings and rankings of 14 pre-
scription opioid medications that resonate with epidemi-
ologic data and clinical experience [21].
The OAS ratings of the 14 opioid products (13 marketed
products and one non-marketed product in the United
States) showed marked differences in their relative attrac-
Table 6: Mean ranks of drugs based on OAS ratings in descending order for confirmation/cross-validation sample
Product order for mean 
composite
Mean rank for mean 
composite
Product order for sum 
composite
Mean rank for sum composite
OxyContin 12.05 OxyContin 12.05
Avinza 10.03 Avinza 10.06
Actiq 8.88 Actiq 8.69
Methadone 8.58 Methadone 8.64
Dilaudid 8.45 MS Contin 8.42
MS Contin 8.31 Dilaudid 8.27
Kadian 7.55 Percocet 7.53
Percocet 7.44 Kadian 7.50
Vicodin 7.38 Vicodin 7.39
Fentanyl matrix patch 6.55 Fentanyl matrix patch 6.34
Talwin NX 6.13 Talwin NX 6.25
Stadol Nasal Spray 5.72 Stadol Nasal Spray 5.75
Suboxone 5.45 Suboxone 5.53
Duragesic fentanyl reservoir patch 2.50 Duragesic fentanyl reservoir patch 2.58Harm Reduction Journal 2006, 3:5 http://www.harmreductionjournal.com/content/3/1/5
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tiveness for abuse. OxyContin was considered the most
attractive of the products rated, while Duragesic was con-
sidered the least attractive of the products rated. Interest-
ingly, the fentanyl matrix patch rated as part of the
validation process was considered relatively more attrac-
tive for abuse than the reservoir formulation used in Dur-
agesic, even though the active ingredient (fentanyl) and
route of delivery (transdermal) were the same.
The OAS demonstrated excellent reliability (internal con-
sistency) and validity in the study samples. It is important
to consider that, in this study, agreement among raters
(typically considered reliability) was itself taken as evi-
dence of validity. Agreement among observers is an
accepted procedure to establish validity in psychometric
questionnaire development where no objective 'gold
standard' or external reference exists against which to
measure a novel measurement tool [19]. Validity was fur-
ther supported by high levels of agreement between heter-
ogeneous groups of stakeholders (substance abusers and
professional counselors), suggesting that the OAS pro-
vides a robust metric of what makes a prescription opioid
attractive for abuse, and permits comparisons of attrac-
tiveness ratings for different products. That the coun-
selors' rankings agreed highly with those of the substance
abusers provides additional confirmation of the external
validity of the ratings. We considered comparing OAS rat-
ings to reported abuse rates as a "gold standard" criterion
measure, but decided against this approach since there is
no accepted method for ranking the abuse rates of mar-
keted opioids based on available data. Also, our findings
suggested that actual abuse rates will relate to factors
intrinsic to the product, measured by the OAS, as well as
factors extrinsic to the product, not captured in the OAS.
Future research could productively explore predicting
actual abuse rates by combining the OAS with a measure
of these extrinsic factors.
The Concept Mapping process identified three dimen-
sions relevant to the abuse liability of an opioid. Two
dimensions highlighted aspects intrinsic to the drug prod-
uct: positive features of the drug preparation (e.g., speed
of onset, duration of effect, extractability) and negative
features of the preparation (e.g. presence of impurities,
presence of antagonist, messy). The third dimension,
called social milieu features of the drug, tapped factors
extrinsic to the drug product (e.g., availability, availability
of alternatives, cost, social stigma). Pilot usability testing
suggested substantial inter-rater variability of items
reflecting these social milieu factors. That is, the social
milieu items seemed sensitive to variation across individ-
uals, time, and geography. Considerable work has been
devoted to the symbolic meaning attributed to specific
drugs by those who misuse them [22]. An understanding
of such symbolic meaning will ultimately be necessary to
comprehend psychological dependence on drugs. How-
ever, the team determined that the OAS would reflect only
factors identified as intrinsic to the drug preparation. This
decision was based on a consideration of several issues.
One issue was that a goal of the OAS was to evaluate spe-
cific features of new products that are either newly on the
market or even not yet available. Comparisons of such
drugs to established, well-known drugs may be problem-
atic. Another issue, at this early stage of scale develop-
ment, was the goal of maximizing inter-rater agreement. It
was felt that the introduction of items known to vary
widely among individuals would adversely affect the
development and psychometric properties of the OAS.
This decision, however, does not imply that we consider
social milieu questions to be irrelevant. Rather, it may
make more sense to explore this important and complex
issue with a separate scale. Nor does this decision suggest
that we believe the OAS to be immune to the effects of
social milieu on its ratings. Clearly, it is possible that
omission of items tapping social milieu may introduce a
threat to construct validity called 'construct under-repre-
sentation' [23]. However, our data suggest that inclusion
of this dimension may seriously hamper the OAS's relia-
bility and ranking agreement among the various stake-
holder groups which may itself introduce other, potential
threats to validity. Future studies will be necessary to
define more completely and to tease out the potentially
differential effects of various aspects of social meaning on
drug selection by those who misuse these substances.
Additionally, the reliability of substance abusers is in
question. The data contain some suggestions that our
sample of substance abusers may not have been entirely
truthful or perhaps not taken the rating task as seriously as
they might have. For example, nearly a quarter of both the
developmental and the confirmation samples claimed
experience with the fentanyl matrix patch, which had not
been available at the time of the study. Whether this is due
Average effect size for each drug with all other drugs Figure 2
Average effect size for each drug with all other drugs.Harm Reduction Journal 2006, 3:5 http://www.harmreductionjournal.com/content/3/1/5
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to a lack of seriousness about the task, misunderstandings
of the research materials, a tendency of substance abusers
towards braggadocio, or some other explanation is
unknown, but such findings raise caution with respect to
other indications of fact or opinion. Of course, these indi-
viduals and their ratings of the drugs are reasons for the
OAS. To remedy this, it is suggested to include as many
substance abusers as possible in future OAS research.
Finally, a note is in order regarding our claim to validity
of the OAS. Quantifying the construct, "attractiveness for
abuse" of medication preparations, has not been
attempted before. This article presents an initial effort to
provide such a measure. Careful attention was paid to
content validity, using Concept Mapping procedures,
inter-rater reliability, internal consistency, criterion valid-
ity and cross validation. Based on these analyses, we feel
confident in claiming that the OAS has good reliability
and validity. Nevertheless, the relative ranking of individ-
ual pharmaceutical products produced by the OAS may
vary according to as yet uninvestigated threats to external
validity (e.g., construct-irrelevant variance), such as raters'
direct experience with a drug or an increased media profile
for a product. Future research could usefully investigate
the nature and impact of such variables on OAS scores.
While the OAS has some limitations, for now, however, it
is a significant step forward in improving our understand-
ing of the attractiveness of opioid medications for abuse.
Providing industries and regulatory agencies with a scale
that can be applied systematically to products in develop-
ment can help address opioid risk management issues
faced by these industries. Furthermore, health profession-
als can apply the OAS to products already in the market in
order to understand better the relative attractiveness of
new products to substance abusers and hence care for
their clients. The OAS may potentially play an important
role in reducing the harmful use of future prescription
opioid products by individuals.
Conclusion
The OAS represents a significant development in assessing
what makes a prescription opioid product attractive or
unattractive for abuse, and for identifying differences in
abuse potential between different products. Such knowl-
edge may help guide the rational development of abuse-
resistant medications, or provide support for decision
makers on how best to regulate prescription opioid prod-
ucts.
Use of the OAS to assess the attractiveness of established
and new prescription opioid products, including modi-
fied-release forms, may provide information of value in
informing the assessment of the relative risks of these
products for abuse. We anticipate that the information
generated will be an important first step in developing ini-
tiatives to manage this risk.
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